 SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 GLOBE NEWSWIRE -- Catalyst Biosciences, Inc. NASDAQ:CBIO the Company today announced the closing of an underwritten public offering of 8,700,000 shares of its common stock, offered at a price of 5.75 per share to the public. The gross proceeds to the Company from this offering were approximately 50 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company. 